Intrinsic value of Achaogen - AKAO

Previous Close

$18.48

  Intrinsic Value

$0.80

stock screener

  Rating & Target

str. sell

-96%

  Value-price divergence*

0%

Previous close

$18.48

 
Intrinsic value

$0.80

 
Up/down potential

-96%

 
Rating

str. sell

 
Value-price divergence*

0%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of AKAO stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.6

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  61.54
  16.70
  15.53
  14.48
  13.53
  12.68
  11.91
  11.22
  10.60
  10.04
  9.53
  9.08
  8.67
  8.30
  7.97
  7.68
  7.41
  7.17
  6.95
  6.76
  6.58
  6.42
  6.28
  6.15
  6.04
  5.93
  5.84
  5.76
  5.68
  5.61
  5.55
Revenue, $m
  42
  49
  57
  65
  74
  83
  93
  103
  114
  126
  138
  150
  163
  177
  191
  205
  221
  236
  253
  270
  288
  306
  325
  345
  366
  388
  411
  434
  459
  485
  512
Variable operating expenses, $m
 
  100
  116
  133
  151
  170
  190
  211
  234
  257
  282
  307
  334
  362
  391
  421
  452
  484
  518
  553
  589
  627
  666
  707
  750
  794
  841
  889
  940
  993
  1,048
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  91
  100
  116
  133
  151
  170
  190
  211
  234
  257
  282
  307
  334
  362
  391
  421
  452
  484
  518
  553
  589
  627
  666
  707
  750
  794
  841
  889
  940
  993
  1,048
Operating income, $m
  -49
  -51
  -59
  -68
  -77
  -87
  -97
  -108
  -120
  -132
  -144
  -157
  -171
  -185
  -200
  -215
  -231
  -248
  -265
  -283
  -301
  -321
  -341
  -362
  -384
  -407
  -430
  -455
  -481
  -508
  -536
EBITDA, $m
  -49
  -51
  -59
  -68
  -77
  -86
  -97
  -108
  -119
  -131
  -143
  -156
  -170
  -184
  -199
  -214
  -230
  -246
  -263
  -281
  -300
  -319
  -339
  -360
  -382
  -404
  -428
  -452
  -478
  -505
  -533
Interest expense (income), $m
  2
  2
  3
  4
  5
  6
  7
  9
  10
  11
  13
  14
  16
  17
  19
  21
  23
  25
  27
  29
  31
  33
  35
  38
  40
  43
  46
  49
  52
  55
  58
Earnings before tax, $m
  -71
  -53
  -62
  -72
  -82
  -93
  -105
  -117
  -129
  -143
  -157
  -171
  -187
  -202
  -219
  -236
  -254
  -272
  -292
  -312
  -332
  -354
  -376
  -400
  -424
  -450
  -476
  -504
  -532
  -563
  -594
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -71
  -53
  -62
  -72
  -82
  -93
  -105
  -117
  -129
  -143
  -157
  -171
  -187
  -202
  -219
  -236
  -254
  -272
  -292
  -312
  -332
  -354
  -376
  -400
  -424
  -450
  -476
  -504
  -532
  -563
  -594

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  146
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  164
  74
  85
  98
  111
  125
  140
  155
  172
  189
  207
  226
  246
  266
  287
  309
  332
  356
  381
  406
  433
  461
  490
  520
  551
  584
  618
  654
  691
  730
  770
Adjusted assets (=assets-cash), $m
  18
  74
  85
  98
  111
  125
  140
  155
  172
  189
  207
  226
  246
  266
  287
  309
  332
  356
  381
  406
  433
  461
  490
  520
  551
  584
  618
  654
  691
  730
  770
Revenue / Adjusted assets
  2.333
  0.662
  0.671
  0.663
  0.667
  0.664
  0.664
  0.665
  0.663
  0.667
  0.667
  0.664
  0.663
  0.665
  0.666
  0.663
  0.666
  0.663
  0.664
  0.665
  0.665
  0.664
  0.663
  0.663
  0.664
  0.664
  0.665
  0.664
  0.664
  0.664
  0.665
Average production assets, $m
  3
  3
  3
  4
  4
  5
  6
  6
  7
  8
  8
  9
  10
  11
  11
  12
  13
  14
  15
  16
  17
  18
  20
  21
  22
  23
  25
  26
  28
  29
  31
Working capital, $m
  140
  -2
  -3
  -3
  -4
  -4
  -4
  -5
  -5
  -6
  -7
  -7
  -8
  -8
  -9
  -10
  -11
  -11
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -19
  -20
  -21
  -22
  -23
  -25
Total debt, $m
  25
  30
  39
  50
  61
  73
  85
  98
  112
  127
  142
  157
  174
  191
  209
  227
  246
  266
  287
  309
  331
  354
  379
  404
  430
  458
  486
  516
  547
  580
  614
Total liabilities, $m
  57
  62
  71
  82
  93
  105
  117
  130
  144
  159
  174
  189
  206
  223
  241
  259
  278
  298
  319
  341
  363
  386
  411
  436
  462
  490
  518
  548
  579
  612
  646
Total equity, $m
  107
  12
  14
  16
  18
  20
  23
  25
  28
  31
  34
  37
  40
  43
  47
  50
  54
  58
  62
  66
  70
  75
  79
  84
  89
  95
  100
  106
  112
  118
  125
Total liabilities and equity, $m
  164
  74
  85
  98
  111
  125
  140
  155
  172
  190
  208
  226
  246
  266
  288
  309
  332
  356
  381
  407
  433
  461
  490
  520
  551
  585
  618
  654
  691
  730
  771
Debt-to-equity ratio
  0.234
  2.500
  2.860
  3.150
  3.390
  3.590
  3.760
  3.900
  4.020
  4.130
  4.220
  4.300
  4.370
  4.430
  4.490
  4.530
  4.580
  4.620
  4.650
  4.690
  4.720
  4.740
  4.770
  4.790
  4.810
  4.830
  4.850
  4.870
  4.890
  4.900
  4.920
Adjusted equity ratio
  -2.167
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162
  0.162

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -71
  -53
  -62
  -72
  -82
  -93
  -105
  -117
  -129
  -143
  -157
  -171
  -187
  -202
  -219
  -236
  -254
  -272
  -292
  -312
  -332
  -354
  -376
  -400
  -424
  -450
  -476
  -504
  -532
  -563
  -594
Depreciation, amort., depletion, $m
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
Funds from operations, $m
  -48
  -53
  -62
  -71
  -82
  -92
  -104
  -116
  -129
  -142
  -156
  -171
  -186
  -201
  -218
  -235
  -253
  -271
  -290
  -310
  -331
  -352
  -374
  -398
  -422
  -447
  -474
  -501
  -530
  -560
  -591
Change in working capital, $m
  -1
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
Cash from operations, $m
  -47
  -53
  -62
  -71
  -81
  -92
  -103
  -116
  -128
  -142
  -155
  -170
  -185
  -201
  -217
  -234
  -252
  -270
  -289
  -309
  -330
  -351
  -374
  -397
  -421
  -446
  -472
  -500
  -529
  -558
  -590
Maintenance CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
New CAPEX, $m
  -1
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
Cash from investing activities, $m
  10
  0
  0
  0
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -5
  -5
Free cash flow, $m
  -37
  -54
  -62
  -72
  -82
  -93
  -105
  -117
  -130
  -143
  -157
  -172
  -187
  -203
  -219
  -236
  -254
  -272
  -292
  -312
  -332
  -354
  -376
  -400
  -424
  -450
  -476
  -504
  -533
  -563
  -594
Issuance/(repayment) of debt, $m
  10
  9
  10
  10
  11
  12
  12
  13
  14
  14
  15
  16
  16
  17
  18
  18
  19
  20
  21
  22
  22
  23
  24
  25
  26
  27
  29
  30
  31
  33
  34
Issuance/(repurchase) of shares, $m
  100
  55
  64
  74
  84
  95
  107
  119
  132
  146
  160
  174
  190
  206
  222
  240
  258
  276
  296
  316
  337
  358
  381
  405
  429
  455
  482
  509
  539
  569
  601
Cash from financing (excl. dividends), $m  
  135
  64
  74
  84
  95
  107
  119
  132
  146
  160
  175
  190
  206
  223
  240
  258
  277
  296
  317
  338
  359
  381
  405
  430
  455
  482
  511
  539
  570
  602
  635
Total cash flow (excl. dividends), $m
  99
  10
  11
  12
  13
  14
  15
  16
  16
  17
  18
  19
  20
  20
  21
  22
  23
  24
  25
  26
  27
  28
  29
  30
  31
  33
  34
  35
  37
  39
  40
Retained Cash Flow (-), $m
  -64
  -55
  -64
  -74
  -84
  -95
  -107
  -119
  -132
  -146
  -160
  -174
  -190
  -206
  -222
  -240
  -258
  -276
  -296
  -316
  -337
  -358
  -381
  -405
  -429
  -455
  -482
  -509
  -539
  -569
  -601
Prev. year cash balance distribution, $m
 
  97
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  52
  -53
  -62
  -71
  -81
  -92
  -104
  -116
  -128
  -142
  -156
  -170
  -185
  -201
  -218
  -235
  -252
  -271
  -290
  -310
  -331
  -352
  -375
  -398
  -422
  -448
  -474
  -502
  -530
  -560
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  50
  -48
  -54
  -59
  -63
  -67
  -70
  -72
  -74
  -74
  -74
  -73
  -71
  -68
  -64
  -60
  -55
  -50
  -45
  -39
  -34
  -29
  -25
  -20
  -16
  -13
  -10
  -8
  -6
  -4
Current shareholders' claim on cash, %
  100
  51.9
  27.0
  14.0
  7.3
  3.8
  2.0
  1.1
  0.6
  0.3
  0.2
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Achaogen, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds that target infections caused by acinetobacter baumannii and pseudomonas aeruginosa; and therapeutic antibody discovery program. The company has development services agreement with ARK Diagnostics, Inc. to co-develop an in vitro assay to measure levels of plazomicin in the blood to enable patients to receive safe and efficacious doses of plazomicin; and license agreement with Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds. Achaogen, Inc. also has a collaboration and license agreement with Crystal Bioscience, Inc. to discover unique monoclonal antibodies against various targets. The company was incorporated in 2002 and is headquartered in South San Francisco, California.

FINANCIAL RATIOS  of  Achaogen (AKAO)

Valuation Ratios
P/E Ratio -9.3
Price to Sales 15.7
Price to Book 6.2
Price to Tangible Book
Price to Cash Flow -14
Price to Free Cash Flow -13.7
Growth Rates
Sales Growth Rate 61.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 37
Current Ratio 0
LT Debt to Equity 19.6%
Total Debt to Equity 23.4%
Interest Coverage -35
Management Effectiveness
Return On Assets -59.7%
Ret/ On Assets - 3 Yr. Avg. -47.7%
Return On Total Capital -74.7%
Ret/ On T. Cap. - 3 Yr. Avg. -56.2%
Return On Equity -94.7%
Return On Equity - 3 Yr. Avg. -66.5%
Asset Turnover 0.4
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -164.3%
EBITDA Margin - 3 Yr. Avg. -122.7%
Operating Margin -116.7%
Oper. Margin - 3 Yr. Avg. -106.8%
Pre-Tax Margin -169%
Pre-Tax Margin - 3 Yr. Avg. -124.3%
Net Profit Margin -169%
Net Profit Margin - 3 Yr. Avg. -124.3%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

AKAO stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the AKAO stock intrinsic value calculation we used $42 million for the last fiscal year's total revenue generated by Achaogen. The default revenue input number comes from 2016 income statement of Achaogen. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our AKAO stock valuation model: a) initial revenue growth rate of 16.7% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for AKAO is calculated based on our internal credit rating of Achaogen, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Achaogen.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of AKAO stock the variable cost ratio is equal to 204.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for AKAO stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 10% for Achaogen.

Corporate tax rate of 27% is the nominal tax rate for Achaogen. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the AKAO stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for AKAO are equal to 6%.

Life of production assets of 10 years is the average useful life of capital assets used in Achaogen operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for AKAO is equal to -4.8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $107 million for Achaogen - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 33.622 million for Achaogen is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Achaogen at the current share price and the inputted number of shares is $0.6 billion.

RELATED COMPANIES Price Int.Val. Rating
TTPH Tetraphase Pha 5.67 0.80  str.sell
EBS Emergent Bioso 34.89 36.73  hold
IONS Ionis Pharmace 46.48 495.91  str.buy
CEMP Cempra 2.85 1.08  str.sell

COMPANY NEWS

▶ Achaogen reports 2Q loss   [Aug-04-17 02:28AM  Associated Press]
▶ ETFs with exposure to Achaogen, Inc. : July 27, 2017   [Jul-27-17 02:09PM  Capital Cube]
▶ Achaogen Announces New Employment Inducement Grants   [Jul-24-17 08:01AM  GlobeNewswire]
▶ ETFs with exposure to Achaogen, Inc. : July 17, 2017   [Jul-17-17 01:34PM  Capital Cube]
▶ ETFs with exposure to Achaogen, Inc. : July 4, 2017   [Jul-04-17 02:27PM  Capital Cube]
▶ ETFs with exposure to Achaogen, Inc. : June 22, 2017   [Jun-22-17 03:17PM  Capital Cube]
▶ ETFs with exposure to Achaogen, Inc. : June 12, 2017   [Jun-12-17 01:47PM  Capital Cube]
▶ Achaogen Announces Closing of Public Offering   [May-31-17 04:01PM  GlobeNewswire]
▶ Plazomicin Granted FDA Breakthrough Therapy Designation   [May-23-17 04:07PM  GlobeNewswire]
▶ Top 4 Pharmaceutical Stocks for 2017   [May-19-17 08:00AM  Investopedia]
▶ Four Stocks Moving On Both News And The Charts   [May-17-17 06:59PM  Forbes]
▶ Achaogen reports 1Q loss   [May-08-17 05:05PM  Associated Press]
▶ ETFs with exposure to Achaogen, Inc. : March 27, 2017   [Mar-27-17 03:47PM  Capital Cube]
▶ Achaogen Adds Janet Dorling as Chief Commercial Officer   [Feb-27-17 09:16AM  GlobeNewswire]
▶ Achaogen Announces Leadership Promotions   [Feb-23-17 04:01PM  GlobeNewswire]
▶ Four Biotech Stocks Breaking Out   [Feb-08-17 01:49PM  at Forbes]
▶ Growth Investing 2017: 3 Stocks to Put on Your Radar   [Jan-31-17 09:14AM  at Motley Fool]
▶ Top 4 Pharmaceutical Stocks for 2017   [Jan-30-17 01:00PM  at Investopedia]
▶ Achaogen Appoints Halley Gilbert to Its Board of Directors   [Jan-05-17 08:30AM  GlobeNewswire]
▶ How Achaogen Inc (AKAO) Stacks Up Against Its Peers   [Dec-19-16 11:50PM  at Insider Monkey]
▶ Stocks to Watch: Achaogen, Inovalon, Valeant   [09:36AM  at The Wall Street Journal]
Stock chart of AKAO Financial statements of AKAO
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.